



Strathprints Institutional Repository

Nelson, L. J. and Treskes, P. and Henderson, C. J. and Homer, N. and Morgan, K. and LeBled, C. and Grant, M. H. and Plevris, J. N. (2014) Human hepatic HepaRG cells maintain high intrinsic CYP450 activity/metabolism and significantly outperform standard HepG2/C3A cells used in drug pharmacology applications. Journal of Hepatology, 60 (1 Supp). S176-S177. ISSN 0168-8278 , [http://dx.doi.org/10.1016/S0168-8278\(14\)60493-1](http://dx.doi.org/10.1016/S0168-8278(14)60493-1)

This version is available at <http://strathprints.strath.ac.uk/57571/>

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (<http://strathprints.strath.ac.uk/>) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to Strathprints administrator: strathprints@strath.ac.uk

Human hepatic HepaRG cells maintain high intrinsic CYP450 activity/metabolism and significantly outperform standard HepG2/C3A cells used in drug pharmacology applications

Philipp Treskes¹, Catherine J Henderson², Natalie Homer², Katie Morgan¹, Claire LeBléd¹, Maria Navarro¹, M Helen Grant³, Leonard J Nelson¹ and John N Plevris¹

¹Hepatology Laboratory, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom; ²Mass Spectrometry Core Laboratory, Wellcome Trust Clinical Research Facility, Queen's Medical Research Institute, Edinburgh, United Kingdom;

³Department of Biomedical Engineering, University of Strathclyde, Glasgow, United Kingdom

BACKGROUND

Tissue Modelling for drug testing

- Conventional *in vitro* human hepatic models for drug testing are based on the use of standard cell lines or primary human hepatocytes (PHHs)
- However, limited availability, inter-donor functional variability and early phenotypic alterations of PHHs *in vitro* restrict their use; whilst cell lines such as HepG2/C3As lack a substantial and variable set of liver-specific functions, specifically, CYP450 activity
- Human HepaRG cells are an alternative organotypic co-culture model of hepatocytes and cholangiocytes that maintains *in vivo*-like liver-specific functions, including intact Phase-I-III drug and lipid metabolism

Objectives

- In this study we compared phenotypic and functional parameters including CYP450 activity and metabolism between HepG2/C3A and human HepaRG cells to assess their value as hepatic models for pre-clinical drug testing
- This approach is aimed at further understanding the suitability of more physiologically-relevant *in vitro* human models to replace or reduce animals in drug pharmacology and toxicology applications

METHODS

Cell culture

- HepG2/C3A or HepaRG were grown to >80% confluence on collagen-I-coated plates and treated (in triplicates) for 24 h With prototypical inducers rifampicin (CYP3A4) and omeprazole (CYP1A2); [n=3]

Cell phenotype

- Cell phenotype was assessed by light-microscopy under phase contrast
- Presence and abundance of CYPs was assessed via dual immunofluorescent and nucleic staining (CYP3A4/ phalloidin/ DAPI)

CYP1A2/ 3A4 Activity

- CYP1A2/3A4 activity was determined using Promega P450-Glo™-Luminescence; and read on a GloMax Multi+ plate reader.
- HepG2/C3A and HepaRG activities were validated by inhibition with specific inhibitors on technical replicates


CYP1A2/ 3A4 Metabolism

- CYP1A2/3A4 metabolism was assessed by challenging the cells with 50 μM testosterone or phenacetin boluses. Supernatant and cell samples were taken after 2 hours of incubation at 37°C.
- Relative turnover and metabolic breakdown were measured via HPLC (Testosterone) and LC-MS/MS (Phenacetin)

RESULTS


Hepatic phenotype

- HepaRG [left panel] and HepG2/C3A [right panel] showed markedly different abundance of CYP3A4, as indicated by immunofluorescent staining against a marker panel consisting of CYP3A4/ phalloidin/ DAPI staining.




CYP1A2/ 3A4 Activity

- HepaRG CYP1A2 and 3A4 activity was manifold higher than that measured in HepG2/C3A cells [grey bars; p<0.001]. In fact relative luminescence measured in HepG2/C3A cells was at levels of blank controls.
- Specificity of CYP induction was confirmed with specific inhibitors [spotted grey bars]: Fluvoxamine [CYP1A2] & Ketoconazole [CYP3A4]



CYP1A2/ 3A4 Metabolism

- HepaRG showed significantly higher turnover of phenacetin 28.5±4.4% vs. 11.7±0.6% [p<0.01] and testosterone 56.5±7.6% vs. 2.0±0.2% [p<0.001]
- as well as more refined metabolic breakdown of phenacetin and testosterone



CONCLUSIONS

Only HepaRG cells retain differentiated morphological/ phenotypic features relevant to drug testing strategies

Analytical techniques including LC-MS/MS allow HepaRG cells to be interrogated for drug reactive metabolite formation – allowing intrinsic (predictive) drug clearance rates to be calculated

HepaRG cells may represent a more physiologically-relevant pre-clinical platform for CYP450 activation/ inhibition, safety pharmacology, as well as drug-drug interaction studies